During the Ukraine Recovery Conference 2025 in Rome, the State Enterprise "Medical Procurement of Ukraine" (MZU) and the international pharmaceutical company Roche signed a historic agreement on localization of production of innovative oncological drugs in Ukraine. About it reported press-service of MZU, write Dengi.ua .
"For the first time our state enterprise becomes a full-fledged partner of the global leader in the development of innovative drugs", - stated in the message.
According to the investment agreement, the Swiss company Roche will supply Ukraine with medicines "in bulk", that is, in ready-to-package form. Final packaging, labeling and delivery of medicines to patients will be carried out on the basis of the branch of MZU "Medpostavki".
It is noted that this will significantly reduce the cost of drugs and increase the number of patients provided with modern treatment. According to Roche's calculations, within 5 years the signed investment agreement will allow to provide medicines to more than 5800 patients.
MHI will procure medicines for the two most common types of oncology in Ukraine:
- atezolizumab ("Tecentric") - for the treatment of non-small cell lung cancer;
- pertuzumab + trastuzumab ("Fesgo") - for the treatment of HER2-positive breast cancer.
It is expected that the first Ukrainian patients will be able to receive drugs with localized production in 2027.